Gill L, Zarbo A, Isedeh P, Jacobsen G, Lim HW, Hamzavi I.
Comorbid autoimmune diseases in patients with vitiligo: a
cross-sectional study....
Simons RE, Zevy DL, Jafferany M. Psychodermatology of
vitiligo: psychological impact and consequences. Dermatol
Ther. 2020;33(3):e13418. https://doi.org/10.1111/dth.13418.
Rodrigues M, Ezzedine K, Hamzavi I, Pandya AG, Harris JE.
New discoveries in the pathogenesis and classification of
vitiligo. J Am Acad Dermatol....
Komen L, Da Graça V, Wolkerstorfer A, De Rie MA, Terwee CB,
Van Der Veen JPW. Vitiligo area scoring index and vitiligo
European task force...
Bergqvist C, Ezzedine K. Vitiligo: a review. Dermatology. 2020;
236(6):571–592. https://doi.org/10.1159/000506103.
Harris JE, Harris TH, Weninger W, Wherry EJ, Hunter CA, Turka
LA. A mouse model of vitiligo with focused epidermal
depigmentation requires...
Strassner JP, Harris JE. Understanding mechanisms of autoimmunity through translational research in vitiligo. Curr Opin
Immunol. 2016;43:81–88....
Searle T, Al-Niaimi F, Ali FR. Vitiligo: an update on systemic
treatments. Clin Exp Dermatol. 2021;46(2):248–258. https://doi.
org/10.1111/ced.14435.
Speeckaert R, Van Geel N. Targeting CTLA-4, PD-L1 and IDO to
modulate immune responses in vitiligo. Exp Dermatol. 2017;
26(7):630–634. https://doi.org/10.1111/exd.13069.
Miao X, Xu R, Fan B, et al. PD-L1 reverses depigmentation in
Pmel-1 vitiligo mice by increasing the abundance of Tregs in
the skin. Sci Rep....
Frisoli ML, Harris JE. Vitiligo: mechanistic insights lead to
novel treatments. J Allergy Clin Immunol. 2017;140(3):654–662.
https://doi.org/10.1016/j.jaci.2017.07.011.
Rashighi M, Agarwal P, Richmond JM, et al. CXCL10 is critical
for the progression and maintenance of depigmentation in a
mouse model of vitiligo....
Howell MD, Kuo FI, Smith PA. Targeting the Janus kinase
family in autoimmune skin diseases. Front Immunol. 2019;10:
2342. https://doi.org/10.3389/fimmu.2019.02342.
Garcia-Melendo C, Cubiró X, Puig L. Janus kinase inhibitors
in dermatology: part 1 — general considerations and
applications in vitiligo and...
Damsky WKB. JAK inhibitors in dermatology: the promise of a
new drug class. J Am Acad Dermatol. 2017;76(4):736–744. https://
doi.org/10.1016/j.jaad.2016.12.005.
Shreberk-Hassidim R, Ramot Y, Zlotogorski A. Janus kinase
inhibitors in dermatology: a systematic review. J Am Acad
Dermatol. 2017;76(4):745–753....
Harris JE, Rashighi M, Nguyen N, et al. Rapid skin
repigmentation on oral ruxolitinib in a patient with coexistent
vitiligo and alopecia areata...
Regazzetti C, Joly F, Marty C, et al. Transcriptional analysis of
vitiligo skin reveals the alteration of WNT pathway: a
promising target...
Kim SR, Heaton H, Liu LY, King BA. Rapid repigmentation of
vitiligo using tofacitinib plus low-dose, narrowband UV-B
phototherapy. JAMA Dermatol....
Hosking AM, Juhasz M, Mesinkovska NA. Topical Janus kinase
inhibitors: a review of applications in dermatology. J Am Acad
Dermatol. 2018;79(3):535–544....
Rothstein B, Joshipura D, Saraiya A, et al. Treatment of vitiligo
with the topical Janus kinase inhibitor ruxolitinib. J Am Acad
Dermatol....
Liu LY, Strassner JP, Refat MA, Harris JE, King BA.
Repigmentation in vitiligo using the Janus kinase inhibitor,
tofacitinib, may require...
Joshipura D, Plotnikova N, Goldminz A, et al. Importance of
light in the treatment of vitiligo with JAK-inhibitors. J Dermatol
Treat. 2018;29(1):98–99....
Joshipura D, Alomran A, Zancanaro P, Rosmarin D. Treatment
of vitiligo with the topical Janus kinase inhibitor ruxolitinib: a
584 ( ...
week open-label extension study with optional narrowband ultraviolet B. J Am Acad Dermatol. 2018;78(6):1205–1207.
https://doi.org/10.1016/j.jaad.2018.02.023...
McKesey J, Pandya AG. A pilot study of 2% tofacitinib cream
with narrowband ultraviolet B for the treatment of facial
vitiligo. J Am Acad...
Mobasher P, Guerra R, Li SJ, Frangos J, Ganesan AK, Huang V.
Open-label pilot study of tofacitinib 2% for the treatment of
refractory vitiligo....
Rosmarin D, Pandya AG, Lebwohl M, et al. Ruxolitinib cream
for treatment of vitiligo: a randomised, controlled, phase 2
trial. Lancet. 2020;396(10244):110–120....
Phan K, Phan S, Shumack S, Gupta M. Repigmentation in
vitiligo using Janus kinase (JAK) inhibitors with phototherapy:
systematic review and...
